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Dear editor,  
With increasingly successful treatment of malignancies, therapy-related leukemia (TRL) and 
myelodysplastic syndrome (MDS) are increasingly observed, especially in association with 
prior radiotherapy, use of alkylating agents or topoisomerase-II inhibitors [1,2]. They are 
characterized by lesions of chromosomes 5 and 7 and poor survival (median 7-10 months) 
[3,4]. Azacitidine may be a reasonable treatment choice [5] although safety concerns in 
patients with complex cytogenetics [6] or previous acute promyelocytic leukemia (APL) exist 
[7].  Here we present a case of two consecutive, individually rare, TRLs following initial solid 
tumor and subsequent treatments with development of unique translocation (13;17)(q12;q25). 
Azacitidine was successfully used achieving one year long remission when patient relapsed 
revealing a distinctive karyotype (Figure 1). 
Female patient aged 61 was diagnosed with breast cancer in 2006. She had mastectomy, 
received 4 cycles of doxorubicin/cyclophosphamide, 4 cycles of paclitaxel and radiotherapy 
accomplishing remission.  
In 2009 APL was diagnosed, PML/RARα positive (47,XX,+8,t(15;17)(q24;q21)[10]). 
Antracycline/ATRA based induction and three consolidation therapies were followed by 2 
year ATRA/6-MP/methotrexate maintenance. Remission was soon achieved and patient 
remained without detectable PML/RARα transcript thereafter. 
In 2013 patient developed anemia requiring transfusion support. MDS (18% blasts) with 
complex cytogenetics (45,XX,del(5)(q22q33),-
7,t(13;17)(q12;q25),del(12)(p13),add(20)(q11)[cp15]) was diagnosed. Azacitidine was 
instituted as salvage therapy and patient became transfusion independent, achieving 
hematological remission. After 11 cycles azacitidine had to be stopped due to development of 
anemia and thrombocytopenia. Repeated revisions showed increased number of blasts (15% 
progressing to 72%) and altered cytogenetics (45,XX,del(5)(q22q33),-
7,t(13;17)(q12;q25),del(12)(p13)[20]). FISH was performed on the actual sample and 
retrospectively (at the time of MDS diagnosis) revealing 12p13 deletion was initially present 
in a subclone comprising 35% of cells and now prevailing in 90% of cells. 17p13 deletion was 
absent in both samples. Patient receives supportive treatment and remains alive more than 18 
months since diagnosis. 
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Several interesting observations emerge from our case. Treatment-related malignancies 
represent a life-long problem reflecting underlying genome instability (obvious weak point at 
chromosome 17). Unique translocation (13;17)(q12;q25), has not been described in MDS 
before and bears unknown prognostic significance (ZNF198, FLT3, BRCA2 and Septin from 
the rearranged chromosomal regions are possible candidate genes). Our heavily pretreated 
patient was successfully treated with azacitidine achieving prolonged remission. Therapy was 
well tolerated and no reactivation of previous APL was observed [7]. However, disease 
control was ultimately lost with the expansion of clone harboring deletion 12p13 (locus of 
TEL/EFV6 gene) rendering azacitidine therapy ineffective. This association has not been 
described so far and implies potential molecular mechanisms worth investigating in further 
studies. No deletion of 17p13 (locus of TP53 gene) was detected, as assessed by FISH. 
Lesions of TP53 [8] and overlapping categories of monosomal and complex karyotype 
[4,9,10] are associated with inferior clinical outcomes in MDS patients treated with 
hypomethylating agents. MDS with complex cytogenetics may also represent entity of higher 
risk for treatment [6] as resulting genome instability and selective action of hypomethylating 
agents on different subpopulations may favor expansion of most resilient clone (accelerating 
transformation to acute leukemia). This puts treating physicians “between Scylla and 
Charybdis” leaving them to choose between “less of two evils”. In our opinion, due to the 
lack of alternative treatment options in this especially unfavorable group of patients, 
azacitidine is still a reasonable choice.  
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Fig.1  
Two distinctive cytogenetic profiles (prior to and after azacitidine treatment) in a patient with 
therapy-related myelodysplastic syndrome and complex cytogenetics. A) Karyotype at time of 
diagnosis was 45,XX,del(5)(q22q33),-7,t(13;17)(q12;q25),del(12)(p13),add(20)(q11)[cp15]. 
Unique translocation (13;17)(q12;q25) has not been described before and bears unknown 
prognostic significance. Number of genes previously recognized in context of myeloid and 
other malignancies are candidates for rearrangement (including ZNF198, FLT3, BRCA2 and 
Septin). B) Karyotype after loss of response to azacitidine was: 45,XX,del(5)(q22q33),-
7,t(13;17)(q12;q25),del(12)(p13)[20]. Deletion 12p13 (locus of TEL/EFV6 gene) was initially 
present in a subclone comprising 35% of cells and now prevailing in 90% of cells. TEL is 
strong transcriptional repressor playing crucial role in hematopoietic regulation. Deletion of 
17p13 was absent in both samples. Aforementioned set of events reflects selective action of 
hypomethylating agents on subpopulations of cells in MDS with complex cytogenetics 
(eradicating subpopulation with altered chromosome 20 and favoring one with partial deletion 
of chromosome 12) and suggests possible molecular mechanisms of drug resistance. Legend: 
single horizontal arrow – del(5)(q22q33); X sign – deletion of chromosome 7; single vertical 
arrow – del(12)(p13); double horizontal and triple horizontal arrows – t(13;17)(q12;q25); 
double vertical arrow – add(20)(q11).  
 
